![]() Atlas Capital Advisors LLC now owns 935 shares of the company’s stock valued at $42,000 after acquiring an additional 275 shares during the period. Atlas Capital Advisors LLC lifted its holdings in shares of 10x Genomics by 41.7% during the second quarter. Ltd bought a new position in shares of 10x Genomics during the first quarter valued at $39,000. ![]() National Bank of Canada FI now owns 611 shares of the company’s stock valued at $34,000 after acquiring an additional 505 shares during the period. National Bank of Canada FI lifted its holdings in shares of 10x Genomics by 476.4% during the first quarter. ![]() Hedge funds and other institutional investors have recently bought and sold shares of the company. According to, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.50. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Finally, Stifel Nicolaus raised their price objective on shares of 10x Genomics from $57.00 to $68.00 in a research note on Thursday, May 4th. They issued an “overweight” rating and a $65.00 price objective on the stock. Barclays initiated coverage on shares of 10x Genomics in a research note on Wednesday, May 10th. They set an “overweight” rating and a $65.00 price target on the stock. Stephens initiated coverage on 10x Genomics in a report on Thursday, March 30th. Several brokerages have commented on TXG. will post -1.42 EPS for the current fiscal year. On average, research analysts forecast that 10x Genomics, Inc. During the same period last year, the business earned ($0.38) earnings per share. The firm’s revenue for the quarter was up 17.3% compared to the same quarter last year. 10x Genomics had a negative return on equity of 22.02% and a negative net margin of 32.51%. The firm had revenue of $134.29 million during the quarter, compared to the consensus estimate of $128.87 million. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.06). Learn more about the CARD Team.10x Genomics ( NASDAQ:TXG – Get Free Report) last issued its earnings results on Wednesday, May 3rd. This expert group is led by Xylena Reed, Ph.D. Denovix CellDrop Automated Cell Counter.The following list contains the modern instrumentation used by this expert group: Single cell Multiome (ATAC + Gene Expression).This expert group primarily focuses on the following areas: Additional spatial gene expression and in situ expression may also be used to visually confirm interesting findings and expand our screening capabilities. Next, this group seeks to expand single cell investigations into new areas as the the technology evolves into scaleable versions of single cell DNA methylation and single cell chromatin conformation. Initial efforts will focus on single cell gene expression (live cells or nuclei from frozen tissue), single cell ATAC (nuclei from live cells or frozen tissue), and single cell multiome (both gene expression and ATAC from the same nuclei). ![]() These differential analyses of single cell data will help lead to a better understanding of AD/ADRD and the prioritization of potential therapeutics. This group aims to identify molecular differences in cell type, expression, and chromatin accessibility between healthy and AD/ADRD affected samples. This expert group is committed to expanding the genetic diversity of samples and is using single cell technologies to create a human brain atlas from hundreds of ancestrally diverse individuals. Single cell sequencing allows for the interrogation of gene expression, chromatin accessibility, and protein expression in cells from both in vitro cultures and frozen tissues. Alzheimer’s disease and Alzheimer’s Disease Related related dementias (AD/ADRD) are complex diseases whose pathogenesis is dependent on many different pathways and cell types. Single cell sequencing technologies have improved significantly in the last 10 years offering new ways to characterize cell types and study molecular profiles in health and disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |